The 10-second takeaway
For the quarter ended March 31 (Q1), Core Laboratories beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew. GAAP earnings per share expanded.
Gross margins grew, operating margins grew, net margins contracted.
Core Laboratories reported revenue of $260.9 million. The 12 analysts polled by S&P Capital IQ foresaw revenue of $247.2 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $234.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.22. The 14 earnings estimates compiled by S&P Capital IQ forecast $1.15 per share. GAAP EPS of $1.22 for Q1 were 8.0% higher than the prior-year quarter's $1.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 37.3%, 100 basis points better than the prior-year quarter. Operating margin was 30.3%, 70 basis points better than the prior-year quarter. Net margin was 21.7%, 130 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $261.5 million. On the bottom line, the average EPS estimate is $1.26.
Next year's average estimate for revenue is $1.06 billion. The average EPS estimate is $5.15.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 631 members out of 643 rating the stock outperform, and 12 members rating it underperform. Among 124 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 124 give Core Laboratories a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Core Laboratories is outperform, with an average price target of $128.79.
Is Core Laboratories the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.
- Add Core Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.